- Home
- DRDB vs AGEN Comparison
DRDB vs AGEN Comparison
Compare DRDB & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DRDB | AGEN |
|---|---|---|
| Founded | 2024 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.9M | 335.6M |
| IPO Year | 2024 | 1999 |
Fundamental Metrics
Financial Performance| Metric | DRDB | AGEN |
|---|---|---|
| Price | $10.79 | $6.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $27.00 |
| AVG Volume (30 Days) | 62.9K | ★ 711.0K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | N/A | $14.41 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $597.54 | ★ $12.07 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $10.42 | $2.71 |
| 52 Week High | $10.78 | $10.19 |
Technical Indicators
Market Signals| Indicator | DRDB | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 63.09 | 48.19 |
| Support Level | $10.50 | $6.66 |
| Resistance Level | N/A | $8.64 |
| Average True Range (ATR) | 0.02 | 0.47 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 100.00 | 49.35 |
Price Performance
Historical ComparisonAbout DRDB Roman DBDR Acquisition Corp. II Ordinary shares
Roman DBDR Acquisition Corp II is a blank check company.
About AGEN Agenus Inc.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.